Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
DocGo operates mobile healthcare services providing on-demand medical transportation, remote patient monitoring, and mobile health clinics primarily across the northeastern United States and the United Kingdom. The company has faced significant operational challenges including contract losses and regulatory scrutiny, reflected in an 85% stock decline over the past year. With a market cap of only $100M against $600M in revenue, the valuation suggests severe distress despite positive free cash flow generation.
DocGo generates revenue through per-transport fees from insurance payors and municipalities, subscription-based remote monitoring contracts with healthcare systems, and fixed-fee government service agreements. The business model relies on labor arbitrage (paramedics and EMTs versus traditional hospital staff), route density optimization to maximize vehicle utilization, and technology platforms that coordinate dispatch and patient data. Pricing power is limited due to insurance reimbursement rate pressure and competitive municipal bidding processes. Gross margins of 35% reflect high variable labor costs and fleet maintenance expenses.
Government contract wins or losses, particularly large municipal healthcare logistics agreements which can represent 10-20% of revenue
Insurance reimbursement rate changes from major payors like Medicare, Medicaid, and commercial insurers
Regulatory developments affecting mobile healthcare licensing, scope of practice for paramedics, or medical transportation requirements
Geographic expansion announcements and market entry execution, particularly in high-density urban markets
Operational metrics including transport volume growth, fleet utilization rates, and cost per transport trends
Regulatory risk from state-level medical transportation licensing requirements, scope of practice restrictions for paramedics providing non-emergency care, and potential federal oversight of remote patient monitoring reimbursement models
Labor market tightness for paramedics and EMTs driving wage inflation that cannot be fully passed through to payors, particularly acute in competitive urban markets
Technology disruption risk from hospital-at-home programs, autonomous medical vehicles, or AI-driven triage systems that could commoditize mobile healthcare coordination
Intense competition from regional ambulance operators, national players like AMR (American Medical Response), and healthcare systems vertically integrating mobile services
Loss of key government contracts to lower-cost bidders, particularly given recent scrutiny of migrant services contracts and municipal budget pressures
Insurance payors developing preferred provider networks or in-house mobile health capabilities that bypass third-party coordinators
Negative ROE of -17% and ROA of -17.5% indicate underlying asset productivity issues or recent write-downs that could signal operational distress beyond reported earnings
Despite positive free cash flow, the 85% stock decline and deeply depressed valuation suggest market concerns about going-concern risks, potential equity dilution, or hidden liabilities not apparent in summary financials
Working capital management risk given accounts receivable concentration with government entities and insurance payors that could face their own budget constraints
low - Healthcare utilization, particularly emergency medical services and chronic disease management, demonstrates counter-cyclical or acyclical characteristics as medical needs persist regardless of economic conditions. However, elective mobile health services and corporate wellness contracts show moderate sensitivity to business spending cycles. Government contract revenue is relatively stable but subject to municipal budget constraints during recessions.
Rising interest rates have moderate negative impact through higher financing costs for fleet expansion and working capital facilities, though the company's low debt-to-equity ratio of 0.11 limits exposure. Rate increases also pressure valuation multiples for unprofitable growth companies, particularly relevant given negative ROE. However, the asset-light model relative to traditional healthcare facilities reduces capital intensity and rate sensitivity compared to hospital operators or skilled nursing facilities.
Moderate credit exposure exists through accounts receivable from insurance payors (typically 60-90 day collection cycles) and government entities (can extend 90-120 days). Tightening credit conditions or municipal budget stress could extend payment cycles or increase bad debt reserves. The company's strong current ratio of 2.59 provides cushion, but cash conversion efficiency is critical given the thin operating margins.
value - The extreme valuation dislocation (0.2x P/S, 0.3x P/B, 81% FCF yield) attracts deep value investors and distressed/special situations funds looking for turnaround opportunities or liquidation value. The 85% drawdown has likely flushed out growth investors. Current holders are likely contrarian value players betting on operational stabilization, asset sales, or takeout potential given the revenue base substantially exceeds market cap.
high - The stock exhibits extreme volatility with 51% decline over six months and 85% over one year, suggesting beta well above 2.0. Small market cap of $100M amplifies price swings on low trading volume. Binary outcomes around major contract decisions, regulatory developments, or going-concern questions drive outsized moves. Options market likely prices elevated implied volatility reflecting distress scenario risk.
